Skip to content

The Study of Qi Zhu fang Fomula Improves the Immune Microenvironment Related to Breast Cancer Macrophages: a randomized, double-blind, placebo-controlled study

The Study of Qi Zhu fang Fomula Improves the Immune Microenvironment Related to Breast Cancer Macrophages: a randomized, double-blind, placebo-controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200005630
Enrollment
Unknown
Registered
2022-02-10
Start date
2022-04-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Placebo Group:Placebo
Qi Zhu fang Fomula Group:Qi Zhu fang Fomula

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ?Female, aged =18 years old and =70 years old; ? Breast B-ultrasound, mammography, MRI, at least one of the results of BI-RADS grading is 4B or above, and the breast specialist judges that surgery or puncture is necessary; ? Have not received any tumor-related treatment, including surgery, radiotherapy and chemotherapy, endocrine therapy, immunotherapy, etc.; ? TCM syndrome differentiation belongs to the type of Qi deficiency and blood stasis; ? With the informed consent of the patient.

Exclusion criteria

Exclusion criteria: ? Those who are unable to cooperate due to mental illness, etc.; ? Patients with serious diseases of the circulatory system, respiratory system, digestive system, blood system, urinary system, nervous system, and endocrine system, and the researchers believe that the serious diseases of the patient's other systems will affect the results of this study; ? Those who refuse surgery and/or puncture; ? Patients with distant metastasis of breast cancer; ? Known to suffer from any other malignant tumor; ? Participate in other clinical investigators during the same period; ? Those who are pregnant or breastfeeding; ? Those who cannot take traditional Chinese medicine due to allergies or other reasons; ? Those who regularly took traditional Chinese medicine in the past three months before the experiment (=5 days per week, =7 days intermittently).

Design outcomes

Primary

MeasureTime frame
Changes in the expression of APOC3 and macrophages M1, M2 by traditional Chinese medicine in malignant tumors;The relationship between the expression of APOC3 in malignant tumors and the expression of M1 and M2 in macrophages;

Secondary

MeasureTime frame
Expression of APOC3 and macrophage M1 and M2 in benign and malignant tumors;The difference between the effects of traditional Chinese medicine on the expression of APOC3 and macrophage M1 and M2 in benign and malignant tumors;Safety index;

Countries

China

Contacts

Public ContactKe Jiang

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

surgeonjk@163.com13301617893

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026